Evidence map›Paper›PMID 28194578›Full record

ReviewAdvances in therapy2017

Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.

Raffaele De Caterina, Walter Ageno, Giuseppe Boriani, Paolo Colonna, Angelo Ghirarduzzi, Giuseppe Patti, Roberta Rossini, Andrea Rubboli, Piercarla Schinco, Giancarlo Agnelli

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Raffaele De CaterinaInstitute of Cardiology and Center of Excellence on Aging, "G. d'Annunzio" University-Chieti, C/o Ospedale SS. Annunziata, Chieti, Italy. rdecater@unich.it.ORCID 0000-0003-1637-574X
Walter AgenoDepartment of Clinical and Experimental Medicine, University of Insubria and Ospedale di Circolo, Varese, Italy.
Giuseppe BorianiCardiology Division, Department of Diagnostics, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
Paolo ColonnaDivision of Cardiology, Hospital Policlinico of Bari, Bari, Italy.
Angelo GhirarduzziDepartment of Internal Medicine I, Angiology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.
Giuseppe PattiDepartment of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy.
Roberta RossiniCardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Andrea RubboliLaboratory of Interventional Cardiology, Division of Cardiology, Ospedale Maggiore, Bologna, Italy.
Piercarla SchincoThrombosis Unit and Hemophilia Center, Department of Oncology, Città della Salute e della Scienza-Molinette hospital, Turin, Italy.
Giancarlo AgnelliVascular and Emergency Medicine and Stroke Unit, University of Perugia, Perugia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

Indexed as

Atrial FibrillationVenous ThromboembolismAge FactorsAnticoagulantsComparative Effectiveness ResearchHumansMedication Therapy ManagementPractice Guidelines as TopicPyridinesThiazolesWarfarinAnticoagulantsedoxabanPyridinesThiazolesWarfarinAtrial fibrillationEdoxabanNon-vitamin K antagonist oral anticoagulantsOral anticoagulantsVenous thromboembolismVitamin K antagonists

Identifiers

PMID28194578
PMCPMC5350200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.